title: Infantile haemangioma: a complicated disease.
abstract: Infantile haemangiomas (IH) are common benign vascular tumors of childhood. They are characterised by rapid growth during the first year of life and slow regression that is usually completed by 7-10 years of age. The underlying mechanism of action of IH is aberrant angiogenesis and vasculogenesis, and involves the mammalian target of rapamycin pathway and vascular endothelial growth factor pathway. IH become a challenge if they are part of a syndrome, are located in certain areas of the body, or if complications develop. The beta-adrenergic receptor blocker propranolol is a promising new candidate for first-line systemic therapy. This review focuses on the clinical characteristics, pathogenesis and management of IH.
authors.forename: Mingke
authors.initials: M
authors.lastname: Qiu
authors.forename: Xianqin
authors.initials: X
authors.lastname: Qi
authors.forename: Yuxin
authors.initials: Y
authors.lastname: Dai
authors.forename: Shuqing
authors.initials: S
authors.lastname: Wang
authors.forename: Zhiwei
authors.initials: Z
authors.lastname: Quan
authors.forename: Yingbin
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of General Surgery, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine,No.1665 Kongjiang Road,200092, Shanghai China, jingminou@yeah.net.
authors.forename: Jingmin
authors.initials: J
authors.lastname: Ou
mesh_terms: D006391:Hemangioma / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D006801:Humans; D009389:Neovascularization, Pathologic; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases